| niacin extended-release formulation / Generic mfg. |
2005-004080-28: Efficacy and Safety of Niaspan in South Asian Stroke Survivors: NIASTAR TRIAL(Niaspan: Indo-Asian Stroke patienT Atherosclerotic Regression trial) |
|
|
| Ongoing | 4 | 280 | Europe | Niaspan, Simvastatin, Niaspan, Simvastatin, Niaspan, Simvastatin | Sandwell Medical Research Unit | 1. Patients diagnosed as having a stroke based on the WHO CriteriaPatients with transient ischaemic attacks will be included if symptoms of motor or sensory loss were demonstrable with full recovery within 24 hours. Only strokes and TIA that are ischaemic in nature (thrombo-embolic) will be included in the study | | | | |
2005-002982-35: The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease |
|
|
| Ongoing | 4 | 40 | Europe | Niaspan, Phosex, Niaspan, PL 14994/0001, Niaspan, Phosex, Niaspan, Phosex | Barts and The London NHS Trust | Chronic renal failure (CKD stages 4 &%) | | | | |
2005-005347-25: Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV |
|
|
| Ongoing | 4 | 130 | Europe | Niaspan, Niaspan | Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel | Women or men > 35 and < 80 years of age with a documented, clinically stable coronary artery disease (CAD) and a flow-mediated vasodilatation (FMD) of less than 8% from the heart catheter register of the department of medicine II, Johannes Gutenberg-University Mainz. | | | | |
2007-000197-24: EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS.SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) –A RANDOMIZED CONTROLLED TRIAL |
|
|
| Ongoing | 4 | 200 | Europe | Simvastatin Merck 40mg, Niaspan 500mg, Simvastatin Merck 40mg 1-24892, Niaspan 500mg Merck 1-25383, Simvastatin Merck 40mg 1-24892, Niaspan 500mg Merck 1-25383 | MUW, Univ.Klinik f. Innere Medizin II, Abteilung f. Angiologie | 200 consecutive patients with PAD and low serum HDL cholesterol levels (<45mg/dL in men, <55 mg/dL in women) will be enrolled in this single-center prospective randomized controlled open-label trial. | | | | |
2008-000465-37: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients. |
|
|
| | 3/4 | 200 | Europe | MK-0524A (ER-Niacin/Laropiprant) 1g/20mg, MK-0524A (ER-Niacin/Laropiprant) 1g/20mg, | Laboratoires Merck Sharp & Dohme - Chibret, Merck Sharp & Dohme GmbH, Merck Sharp & Dohme de España, S.A., MSD BV | Dyslipidemia | | 07/08 | | |
2010-021627-27: A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipids |
|
|
| Ongoing | 3 | 1424 | Europe, RoW | Tablet, Tredaptive 1000 mg/20 mg modified-release tablets | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP., , Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | Primary Hypercholesterolemia or Mixed Dyslipidemia, High blood cholesterol or high concentration of lipids in the blood., Body processes [G] - Metabolic Phenomena [G03] | | | | |
Niaspan, NCT01041053: Flexible Doses of Niacin () as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis |
|
|
| Recruiting | 3 | 90 | Canada | Niaspan | Capital District Health Authority, Canada | Cognition | 01/14 | | | |
2006-000569-13: Influence on the coronary Microcirculation and on myocArdial perfusion Reserve of Niaspan given IN addition to simvastatin in diabEtic patients |
|
|
| Ongoing | 3 | 40 | Europe | Tablet | Cardioangiologisches Centrum Bethanien | Diabetic patients at high risk for CVD | | | | |
2005-004218-34: Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins |
|
|
| Ongoing | 3 | 46 | Europe | NIASPAN, NIASPAN, NIASPAN | Department of Cardiology, UK Aachen | coronary artery disease and lipid disorder | | | | |
2007-002023-32: Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia |
|
|
| Ongoing | 2 | 30 | Europe | Niaspan 500 mg, Niaspan 1000 mg, Niaspan 500 mg, Niaspan 1000 mg | Charité - Universitätsmedizin Berlin | Patients in this study do have symptomes like dyspnea, reduced maximum stress and do have a weakness feeling.We are analysing the endothelial function via the FMD-methode: Before and after a Niaspan-treatment of 6 months. | | | | |
2007-006393-29: A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides. |
|
|
| Ongoing | 2 | 120 | Europe | V0002 CA, V0002 CA, Niaspan® 375mg Prolonged Release, Niaspan® 500mg Prolonged Release, Niaspan® 750mg Prolonged Release, Niaspan® 1000mg Prolonged Release, Niaspan® 375mg Prolonged Release, Niaspan® 500mg Prolonged Release, Niaspan® 750mg Prolonged Release, Niaspan® 1000mg Prolonged Release | PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre | Dyslipidemia with uncontrolled elevated triglycerides | | | | |
| Recruiting | 2 | 60 | RoW | conventional treatment, conventional treatment ( anti diabetic drugs and antihyperlipidimic drugs ), Furosemide or other alternatives , Niaspan or other alternatives, conventional therapy, Trimetazidine, furosemide or other alternative , niaspan or other alternative | October 6 University | Non-Alcoholic Fatty Liver Disease | 06/24 | 09/25 | | |
NCT05846373: Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine |
|
|
| Recruiting | 2 | 66 | RoW | Nicotinic Acid 500 MG Extended Release Oral Tablet, Niacin, Nicotinic Acid 1000 MG Extended Release Oral Tablet, Placebo | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Migraine Prophylaxis | 01/24 | 01/24 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
